My CPNP provides quick access to the most important features on cpnp.org.
You will see your important notices, and you will have direct access to your exams and other action items.
Log in now to see your personalized page.
Lin C-H, Chen P-K, Chang Y-C, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75(9):678-85. doi:10.1016/j.biopsych.2013.08.010.
BACKGROUND: N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital for learning and memory. Hypofunction of NMDAR has been reported to play a role in the pathophysiology of Alzheimer disease (AD), particularly in the early phase. Enhancing NMDAR activation might be a novel treatment approach. One of the methods to enhance NMDAR activity is to raise the levels of NMDA coagonists by blocking their metabolism. This study examined the efficacy and safety of sodium benzoate, a D-amino acid...
Najjar S, Pearlman DM, Hirsch S, et al. Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report. Biol Psychiatry. 2014;75(12):e23-6. doi:10.1016/j.biopsych.2013.07.041.
If you have any questions, please contact us.